Health  Vol.6 No.1 , January 2014
Effects of flu vaccine, solely or accompanied by pneumovax-23 vaccine on clinical consequences of the respiratory diseases among Iranian pilgrims in Hajj
Abstract: Background: Respiratory disorders are the most common diseases among Iranian pilgrims in Hajj. Some studies recommended flu and pneumococcal vaccines separately or in combination to reduce respiratory diseases occurrence and its morbidity. These effects are not clear in afflicted Hajj pilgrims. Objective: This is a cohort study that investigates the effects of above-mentioned vaccines each or their combination on respiratory syndromes and their consequences among Iranian pilgrims in Mecca. Method: The participants were 295 Iranian pilgrims from the beginning to the end of the journey. They were systematically observed for getting afflicted with a respiratory syndrome or not. In this study, we have assessed the effects of flu and pneumococcal vaccines on respiratory disease occurrence and on 8 clinical consequences including as: the duration of fever, duration of cough, duration of bed rest, presence of post nasal discharge and dirty sputum, the total disease length, and the number of referrals to the hospital, physician’s visits and complications. The data for this study were gathered through a questionnaire with 14 basic questions and 60 choices. This was processed using the SPSS software of 11.5 version, T- and Chi-square tests. Results: The results showed no significant correlations between the above-mentioned factors and vaccination with one or both flu and pneumovax-23 except for the duration of coughs which was significantly reduced in all cases (p < 0.01) and also decreased complications of the disease (p < 0.001). Conclusion: The study suggests the high-risk groups, should be vaccinated with combination of flu and pneumovax-23 vaccines in Hajj.
Cite this paper: Dabiran, S. , Razavi, S. , Kashani, A. , Karbakhsh, M. , Naser-Hodjati, H. and Peyafarin, F. (2014) Effects of flu vaccine, solely or accompanied by pneumovax-23 vaccine on clinical consequences of the respiratory diseases among Iranian pilgrims in Hajj. Health, 6, 123-127. doi: 10.4236/health.2014.61019.

[1]   [1] Centers for Disease Control and Prevention (CDC) (2001) Risk for meningococcal disease associated with the Hajj 2001. Morbidity and Mortality Weekly Report, 50, 97-98.

[2]   Razavi, M., Sadeghi-Hassanabadi, M. and Salamati, P. (2005) The comparison of influenza vaccine efficacy on respiratory disease among Iranian pilgrims. Acta Medica Iranica, 43, 1-3.

[3]   Meysamie, A., Ardakani, H.Z., Razavi, S.M. and Doroodi, T. (2006) Comparison of mortality and morbidity rates among Iranian pilgrims in Hajj 2004 and 2005. Saudi Medical Journal, 27, 447-451.

[4]   Rubins, J.B. and Janoff, E.N. (2001) Pneumococcal disease in the elderly: What is preventing vaccine efficacy? Drugs Aging, 18, 305-311.

[5]   Vila-Corcoles, A., Ochoa-Gondar, O., Hospital, I., Ansa, X., Vilanova, A., Rodriquez, T. and Llor, C., Evan Study Group (2006) Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population. Clinical Infectious Diseases, 43, 860-886.

[6]   Granger, R., Walters, J., Poole, P.J., Lesserson, T.J., Manqtani, P., Cates, C.J. and Wood-Baker, R. (2006) Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, 11, Article ID: CD00139.

[7]   Mykietiuk, A., Garratala, J., Domingez, A., Manzur, A., Fernandez-Sabe, N., Dorca, J., Tubau, F., Mensesa, F. and Gudiol, F. (2006) Effect of prior pneumococcal vaccination on clinical outcome of Hospitalized adults with community-acquired pneumococcal pneumonia. European Journal of Clinical Microbiology & Infectious Diseases, 25, 457-462.

[8]   Bulter, J.C., Breiman, R.E., Campbell, J.F., Lipman, H.B., Broome, C.V. and Facklam, R.R. (1993) Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA, 270, 1826-1831.

[9]   Centers for Disease Control and Prevention (CDC) (2006) Influenza and pneumococcal vaccination coverage among persons aged > 65 years in United States, 2004-2005. Morbidity and Mortality Weekly Report, 55, 1065-1068.

[10]   Razavi, S.M., Ziaee, H. and Sedaghat, M. (2004) Morbidity and mortality among Iranian pilgrims and factors involved, in Hajj 2003. Journal of the Faculty of Medicine, 62, 1.

[11]   Puhakka, T., Lavonius, M., Varpula, M., Svedstrom, E., Terho, E. and Ruuskanen, O. (2001) Pulmonary imaging and function in the common cold. Scandinavian Journal of Infectious Diseases, 33, 211-214.

[12]   Razavi, S.M., Dabiran S. and Ardekani, H.Z. (2004) The incidence of influenza like Illness and determination of the efficacy of fluvaccine in Iranian pilgrims during Hajj pilgrimage. Acta Medica Iranica, 42, 397-401.

[13]   Spike, J.S., Fedson, D.S. and Facklam, R.R. (1990) Pneumococcal vaccination; controversies and opportunities. Infectious Disease Clinics of North America, 4, 11-27.

[14]   Ansaldi, F., Turello, V., Lai, P., Bastone, G., Deluca, S., Rossell, R., Durando, P., Sticch, L., Gasparini, R., Delfino, E. and Icardi, G. (2005) Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people. Journal of International Medical Research, 33, 490-500.

[15]   Melton, K.A. (2001) Pneumococcal vaccine. Primary Care Update for OB/GYNS, 8, 44-47.